Latest Conference Articles

November 13th 2016, 1:31am

AASLD Liver Meeting

Efforts are under way to further evaluate the effects of regorafenib on sorafenib-resistant HCC cells, including the role of suppressing the ERK signaling pathway.

November 13th 2016, 1:16am

SITC Meeting

Joaquim Bellmunt, MD, PhD, attending physician of Solid Tumor Oncology at Dana-Farber Cancer Institute, discusses findings from the phase III KEYNOTE-045 study, which compared second- or third-line pembrolizumab with investigator-choice chemotherapy as a treatment for patients with metastatic or locally advanced, unresectable urothelial carcinoma.

November 13th 2016, 12:26am

AASLD Liver Meeting

Stevan A. Gonzalez, MD MS, clinical assistant professor, department of internal medicine, Texas A&M College of Medicine, medical director of liver transplantation, Simmons Transplant Institute, Baylor All Saints Medical Center, discusses a cost effectiveness analysis of treating hepatitis C patients with hepatocellular carcinoma (HCC) before or after a liver transplant.

November 12th 2016, 7:06pm

PER® New York Lung Cancer Symposium

Lung cancer treatment has undergone a game-changing transformation within the past few years, with a burst of FDA approvals of targeted agents and immunotherapies across a number of indications.

November 10th 2016, 5:20am

SMR Congress

Rodabe N. Amaria, MD, assistant professor Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the results of a recent trial testing neoadjuvant and adjuvant dabrafenib plus trametinib versus standard of care in high-risk resectable BRAF-mutant melanoma.

November 10th 2016, 3:06am

SMR Congress

Results from a safety, tolerability, and dose escalation phase Ib/II study involving intratumoral SD-101 and pembrolizumab (Keytruda) have demonstrated that the combination was well-tolerated with no dose-limiting toxicities.

November 10th 2016, 2:48am

SMR Congress

Treatment with the combination of dabrafenib and trametinib before and after surgery demonstrated a dramatic improvement in relapse-free survival compared with the standard of care for patients with stage IIIb/c or oligometastatic BRAF-mutant melanoma.

November 10th 2016, 2:22am

SMR Congress

Keith T. Flaherty, MD, director of the Termeer Center for Targeted Therapy, Massachusetts General Hospital and professor of Medicine, Harvard Medical School, discusses the results from the COLUMBUS trial, testing encorafenib plus binimetinib compared to vemurafenib or encorafenib as single agents.

November 10th 2016, 1:53am

SMR Congress

Bin Zheng, PhD, assistant professor of Dermatology at Harvard Medical School and assistant biologist at Massachusetts General Hospital, discusses the potential for phenformin, a drug created for Type 2 diabetes, to be used for patients with melanoma.

November 9th 2016, 8:10pm

SMR Congress

The combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib reduced the risk of progression or death by 46% compared with vemurafenib (Zelboraf) for patients with BRAF-mutant unresectable melanoma.

November 9th 2016, 5:18am

SMR Congress

The combination of nilotinib and trametinib proved to be synergistic in BRAF/NRAS wild-type melanoma.

November 9th 2016, 5:07am

SMR Congress

The combination of dabrafenib and trametinib continued to demonstrate durable efficacy for patients with BRAF V600E/K-mutant melanoma across patient subgroups in a 3-year analysis of the phase III COMBI-d study, with baseline site of metastasis identified as a predictor of overall survival ≥36 months,

November 9th 2016, 1:47am

SMR Congress

Graham Mann, MBBS, PhD, FRACP, professor of Medicine, Westmead Clinical School and co-director of the Centre for Cancer Research, The Westmead Institute for Medical Research at the University of Sydney in Australia, discusses his findings from the Australian Melanoma Genome Project, which were presented at the 2016 Society for Melanoma Research (SMR) Congress.

November 9th 2016, 1:14am

SMR Congress

Stefani Spranger, PhD, postdoctoral fellow at the University of Chicago, discusses recent findings about why a certain subgroup of patients with melanoma do not have T cells within their tumor microenvironment.

November 8th 2016, 11:38pm

SMR Congress

Helmut Schiader, MD, discusses why drug resistance may be due to epigenetic changes and not mutation-induced changes, as well as the role of immunotherapy/targeted therapy combinations in combating resistance.

November 8th 2016, 5:39am

SMR Congress

The combination of atezolizumab and cobimetinib may lead to a higher overall response and a longer progression-free survival than either agent alone in patients with metastatic melanoma.

November 8th 2016, 5:00am

SMR Congress

Christian Blank, MD, PhD, Netherlands Cancer Institute, discusses some of the early findings from the OpACIN trial testing a combination of ipilimumab and nivolumab in the neoadjuvant and adjuvant setting for patients with stage III melanoma.

November 8th 2016, 4:12am

SMR Congress

Neoadjuvant therapy with the combination of nivolumab and ipilimumab is plausible and effective but can induce a high level of adverse events calling for further research into better tolerated dosing schemes.

November 8th 2016, 3:33am

LUGPA Annual Meeting

Clinical research in private practice is thriving and the future is bright.

November 8th 2016, 2:46am

SMR Congress

Ryan Sullivan, MD, Massachusetts General Hospital, discusses how best to treat patients with melanoma who have the BRAF mutation.